- Home
- ABTS vs LIXT Comparison
ABTS vs LIXT Comparison
Compare ABTS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- LIXT
- Stock Information
- Founded
- ABTS 2010
- LIXT 2005
- Country
- ABTS Hong Kong
- LIXT United States
- Employees
- ABTS N/A
- LIXT N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- LIXT Health Care
- Exchange
- ABTS Nasdaq
- LIXT Nasdaq
- Market Cap
- ABTS 4.6M
- LIXT 4.1M
- IPO Year
- ABTS N/A
- LIXT N/A
- Fundamental
- Price
- ABTS $2.52
- LIXT $1.25
- Analyst Decision
- ABTS
- LIXT
- Analyst Count
- ABTS 0
- LIXT 0
- Target Price
- ABTS N/A
- LIXT N/A
- AVG Volume (30 Days)
- ABTS 30.6K
- LIXT 7.9K
- Earning Date
- ABTS 12-31-2024
- LIXT 05-20-2025
- Dividend Yield
- ABTS N/A
- LIXT N/A
- EPS Growth
- ABTS N/A
- LIXT N/A
- EPS
- ABTS N/A
- LIXT N/A
- Revenue
- ABTS $6,711,225.00
- LIXT N/A
- Revenue This Year
- ABTS N/A
- LIXT N/A
- Revenue Next Year
- ABTS N/A
- LIXT N/A
- P/E Ratio
- ABTS N/A
- LIXT N/A
- Revenue Growth
- ABTS 299.11
- LIXT N/A
- 52 Week Low
- ABTS $0.25
- LIXT $1.02
- 52 Week High
- ABTS $4.19
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- ABTS 49.38
- LIXT 48.44
- Support Level
- ABTS $2.28
- LIXT $1.14
- Resistance Level
- ABTS $3.10
- LIXT $1.31
- Average True Range (ATR)
- ABTS 0.44
- LIXT 0.10
- MACD
- ABTS -0.03
- LIXT -0.00
- Stochastic Oscillator
- ABTS 38.64
- LIXT 31.25
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.